XENE ~−25%: psychiatry enrollment pause (MDD/bipolar) + azetukalner focal-seizure NDA

[LondonNewsTrader]

Biotech binary into two headlines at once — safety pause on psych, filing on epilepsy.

Company PR (17 Sep): Xenon (XENE) voluntarily paused new enrollment in Phase 3 major-depressive-disorder and bipolar-depression trials of azetukalner after a review of neuropsychiatric AEs (confusion, aphasia, ataxia; a small number of reversible psychosis cases reported). Patients already in those studies continue. Same day: Xenon submitted the NDA for azetukalner in focal seizures — the epilepsy franchise is framed as unaffected. Street reaction into/through 18 Sep session roughly −20% to −25% vs prior levels; Deutsche cut to Hold / $46 PT (from Buy / $90), Wedbush cut PT to $55, kept Outperform.

Scalper read: this is a valuation-reset on the psych optionality, not an epilepsy kill — don’t mash the NDA filing with the pause. Watch whether the flush finds a seller-exhaustion bounce or keeps selling on every uptick; size vs. biotech liquidity, not the dual-headline noise.

Source (fair paraphrase): Xenon PR / GlobeNewswire 17 Sep 2026; Reuters on the enrollment pause; Street notes via MarketScreener.

Fading the open flush into the NDA narrative, or treating psych pause as the dominant tape for days?
Anyone tracking relative vs. other CNS names on the AE language?